Baker BROS. Advisors LP Makes New Investment in VYNE Therapeutics Inc. $VYNE

Baker BROS. Advisors LP purchased a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 851,353 shares of the company’s stock, valued at approximately $285,000. Baker BROS. Advisors LP owned approximately 2.56% of VYNE Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in VYNE. Velan Capital Investment Management LP acquired a new position in VYNE Therapeutics in the second quarter worth approximately $50,000. Patient Square Capital LP lifted its stake in VYNE Therapeutics by 23.3% in the second quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock valued at $523,000 after acquiring an additional 60,000 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in VYNE Therapeutics in the second quarter valued at approximately $176,000. TFG Asset Management GP Ltd bought a new stake in VYNE Therapeutics in the second quarter worth approximately $190,000. Finally, Jane Street Group LLC bought a new stake in VYNE Therapeutics in the second quarter worth approximately $206,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Wall Street Zen upgraded shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, VYNE Therapeutics currently has an average rating of “Reduce” and an average price target of $4.50.

VYNE Therapeutics Stock Performance

VYNE Therapeutics stock opened at $0.59 on Friday. VYNE Therapeutics Inc. has a 52 week low of $0.28 and a 52 week high of $1.99. The firm has a market capitalization of $19.70 million, a PE ratio of -0.76 and a beta of 2.00. The business’s 50-day simple moving average is $0.58 and its 200-day simple moving average is $0.45.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.